(Reuters) - Nestle believes its Health Science unit will eventually generate annual sales of 10 billion Swiss francs ($10.3 billion). It already has sales of more than 2 billion francs.
Here are some of its recent deals:
- Sept 2016: Staged acquisition of Phagenesis, a medical device company with a treatment for dysphagia, the inability to swallow safely.
- May 2016: Licensing deal worth up to 100 million euros with DBV Technologies to develop and market an experimental milk allergy test for infants.
- April 2016: Participated in $16.5 million financing round by Enterome Bioscience for an experimental microbiome-based therapy for inflammatory bowel diseases.
- Feb 2016: Investment of $42.5 million in Pronutria Biosciences, now Axcella Health, a specialist in developing medicines for disease caused by amino acid imbalance.
- Jan 2016: Deal with Seres Therapeutics for its microbiome-based treatments for C. difficile infection and inflammatory bowel disease, potentially worth over $1.9 billion.
- Sept 2015: Licensing agreement with Lipid Therapeutics for exclusive worldwide rights, except for Europe and Australia, to its experimental medicine for ulcerative colitis.
- May 2015: Partnership with Flagship Ventures and investment in the firm's Ventures Fund V, a $537 million fund that has interests in nutritional therapy.
- Feb 2013: Acquisition of Pamlab, maker of medical food products for patients with mild cognitive impairment, depression and diabetic peripheral neuropathy.
- Nov 2012: Joint venture with Chi-Med to develop and sell botanical gastrointestinal drugs and nutritional products through access to its library of Chinese medicine.
- July 2012: Purchase of stake in Accera, a supplier of medical foods for patients with neurodegenerative disorders, including its Axona milkshake for Alzheimer's patients.
- July 2011: Bought stake in Vital Foods, a developer of kiwifruit-based products for gastrointestinal conditions.
- May 2011: Acquisition of Prometheus Laboratories, a specialist in gastrointestinal drugs and diagnostics, focusing on conditions such as Crohn's disease and ulcerative colitis.
- August 2010: Acquisition of Vitaflo, provider of nutritional products for patients with genetic metabolic disorders requiring highly restrictive diets.
($1 = 0.9699 Swiss francs)
(Reporting by Martinne Geller and Ben Hirschler in London; editing by Anna Willard)